Abvc Biopharma, Inc.
ABVC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173313
No open-market purchases or sales by Abvc Biopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.72M in total; no superinvestor holds it.
Other share classesECOC
13F holders, Q1 2026
Institutional positions in Abvc Biopharma, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- 0 vs. Q4 2025
- Shares held
- 816.5K
- +249.6K (+44.0%) vs. Q4 2025
- Total value
- $792.1K
- −$415.6K (−34.4%) vs. Q4 2025
- New holders
- 6
- 2 more added
- Sold out
- 6
- 2 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ABVC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $1.72M |
| Q1 2026 | 13 | $792.1K |
| Q4 2025 | 14 | $1.82M |
| Q3 2025 | 14 | $2.39M |
| Q2 2025 | 9 | $817.4K |
| Q1 2025 | 10 | $304.7K |
| Q4 2024 | 13 | $241.0K |
| Q3 2024 | 9 | $155.9K |
| Q2 2024 | 11 | $170.6K |
| Q1 2024 | 8 | $332.6K |
| Q4 2023 | 8 | $128.5K |
| Q3 2023 | 9 | $79.8K |
| Q2 2023 | 9 | $304.2K |
| Q1 2023 | 9 | $421.1K |
| Q4 2022 | 9 | $377.0K |
| Q3 2022 | 11 | $571.0K |
| Q2 2022 | 5 | $1.66M |
| Q1 2022 | 4 | $1.17M |
| Q4 2021 | 5 | $1.56M |
| Q3 2021 | 9 | $521.0K |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Abvc Biopharma, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 221,169 | $214.6K | 0.00% | +18,804+9.3% | Added |
| Vanguard Capital Management LLC | 190,574 | $184.9K | 0.00% | +190,574 | New |
| Vanguard Fiduciary Trust Co | 97,363 | $94.4K | 0.00% | +97,363 | New |
| Renaissance Technologies LLC | 95,100 | $92.3K | 0.00% | −19,163−16.8% | Reduced |
| State Street Corp | 72,800 | $70.6K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 56,442 | $54.8K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 32,087 | $31.1K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 21,023 | $20.4K | 0.00% | +21,023 | New |
| Dimensional Fund Advisors LP | 12,227 | $11.9K | 0.00% | +12,227 | New |
| Squarepoint Ops LLC | 10,547 | $10.2K | 0.00% | +10,547 | New |
| Tower Research Capital LLC (TRC) | 5,423 | $5.26K | 0.00% | +2,230+69.8% | Added |
| UBS Group AG | 1,771 | $1.72K | 0.00% | −817−31.6% | Reduced |
| Royal Bank of Canada | 17 | $0 | 0.00% | +17 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −55,543−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −11,261−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −10,867−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −5,175−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −196−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −189−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |